You are here
AdvaMed Applauds FDA User Fee Sequester Relief, Device Tax Repeal Language in Budget Deal
Permanent Solution to User Fee Issue and Device Tax Repeal Urged
WASHINGTON, D.C. – Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement today on the bipartisan federal budget agreement for fiscal years 2014 and 2015:
“AdvaMed commends Chairmen Patty Murray (D-WA) and Paul Ryan (R-WI) and the other members of the Senate/House budget negotiation committee for their work in crafting a bipartisan budget agreement which replaces the sequester, allows FDA to access the full amount of user fees paid by industry for FYs 2014 and 2015, and calls for repeal of the medical device tax.
“Because of the sequester, FDA’s device center lost $2.9 million in industry user fees in FY 2013. While the budget deal spares user fees for the next two years, unless a permanent solution is found, the agency stands to lose significantly more user fee funds in FY 2016 and beyond. For that reason, AdvaMed strongly supports bipartisan legislation introduced by Sens. Mark Pryor (D-AR) and Roy Blunt (R-MO) and Reps. Leonard Lance (R-NJ) and Anna Eshoo (D-CA) that would address this situation.
“AdvaMed believes user fees paid by industry to FDA should not be treated the same way as taxpayer dollars. We urge Congress to advance a permanent solution in January to allow FDA to access all user fees paid by industry, and we support efforts to release those FY 2013 user fees the agency has been unable to utilize.
“AdvaMed is encouraged that the budget deal preserves language from the Senate Budget Resolution calling for repeal of the medical device tax. We look forward to working with lawmakers on both sides of the aisle moving forward to achieve repeal of this tax which continues to cost our country jobs and to stifle medical innovation.”
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies.